EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Personnel
CompuGroup Medical bundles data-based solutions with ambulatory information systems and appoints Daniela Hommel as CFO
Dr. Eckart Pech, Managing Director Consumer & Health Management Information Systems, is leaving the company at his own request as of March 2024 after the successful build-up phase of the data business. Since joining the company in November 2019, Eckart Pech had initially driven the expansion of the telematics infrastructure in Germany. With the increasing relevance of data usage to support physicians, he was responsible for the establishment and successful expansion of the data business. Also effective as of March 2024, the Board of Directors appoints Daniela Hommel as Chief Financial Officer. Daniela Hommel has held various finance and controlling positions in the Fresenius Group since 2012. Since 2018 she was responsible for the performance of the Fresenius Helios segment as Chief Financial Officer. In 2022, she assumed the role of Chief Financial and Innovation Officer of Helios Global Health GmbH with the aim of improving access to healthcare worldwide with new forms of care. In addition, she has assumed business responsibility for Fresenius' digital daughter Curalie as CEO since 2022. Prior to that, she spent 14 years at KPMG, most recently as the responsible audit partner in the healthcare sector. Until she joins CompuGroup Medical, CEO Michael Rauch will continue to be responsible for the CFO role on an interim basis. Frank Gotthardt, founder of CGM and Chairman of the Board of Directors, commented, "CGM remains a driver of digitization in healthcare, both nationally and internationally. Data-based solutions and artificial intelligence will play a decisive role in the future. With Daniela Hommel, we are gaining an excellent financial expert with experience in the healthcare sector. I would like to expressly thank Eckart Pech for his important contributions to CGM's success, especially in building data-based solutions. We wish him all the best for the future." Michael Rauch adds: "While integrating the CHS business activities into the AIS segment, the focus is on the added value for physicians, whom we support in the digitization of healthcare. I look forward to working with Daniela Hommel, thank Eckart Pech for the excellent collaboration over the past four years and wish him all the best as well."
CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.130 billion in 2022, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 21 countries and products in 60 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.
05.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1741763 |
End of News | EQS News Service |
|
1741763 05.10.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.